Scarica l'app Stockscreener
8.79
1.03%
0.09
Pre-mercato:
8.79
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentOutstanding stock performance - Autocar Professional
What drives Corbus Pharmaceuticals Holdings Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com
Why Corbus Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionElite Stock Shortlist - Newser
Corbus Pharmaceuticals Holdings Inc. Stock Analysis and ForecastMarket-leading profit generation - jammulinksnews.com
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockOutstanding yields - jammulinksnews.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance
(CRBP) Proactive Strategies - news.stocktradersdaily.com
why corbus pharmaceuticals holdings inc. stock attracts strong analyst attentionCapital Safe Stock Watchlist - Newser
What makes Corbus Pharmaceuticals Holdings Inc. stock price move sharplyPotential Rocket List - Newser
How Corbus Pharmaceuticals Holdings Inc. stock performs during market volatilityLow Risk ROI Maximization - Newser
(CRBP) Long Term Investment Analysis - news.stocktradersdaily.com
Bullish Sentiment Across The Cannabis SpaceCheck Full Movers For July 9, 2025 - Benzinga
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Corbus begins multiple ascending dose portion of CRB-913 obesity trial - Investing.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell Small Cap Completeness Index - MarketScreener
How the (CRBP) price action is used to our Advantage - news.stocktradersdaily.com
Cannabis Stock Movers For June 27, 2025 - Benzinga
Corbus Pharmaceuticals Initiates PD-1 Combination Cohort in Phase 1 Study of CRB-701 for Solid Tumors - Quiver Quantitative
Corbus Cancer Drug Shows Promise: New Phase 1 Trial Combines Novel Nectin-4 ADC With Keytruda - Stock Titan
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium - GlobeNewswire
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $50.88 - Defense World
Bank of America Corp DE Buys 7,207 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
11,027 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Bought by Two Sigma Advisers LP - Defense World
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Dermatomyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Acquires 11,400 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
BNP Paribas Financial Markets Makes New Investment in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):